Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson disease

• Published in: Neuroscience letters Vol. 750; p. 135769
• Main Authors: Kakoty, Violina, K C, Sarathlal, Dubey, Sunil Kumar, Yang, Chih Hao, Kesharwani, Prashant, Taliyan, Rajeev
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 17.04.2021
• Subjects: Animals; Blood brain barrier; Genetic Therapy - methods; Humans; Lentiviral vector; Lentivirus - genetics; Parkinson disease; Parkinson Disease - genetics; Parkinson Disease - therapy; Transfection - methods; Parkinson disease; Blood brain barrier; Lentiviral vector
• ISSN: 0304-3940; 1872-7972
• DOI: 10.1016/j.neulet.2021.135769

•Continual strategies to devise therapeutic cure for Parkinson disease (PD) has been a challenge.•The breakthrough of controlled gene delivery technique can bring forth tremendous implications for the treatment of PD.•Lentiviral vectors (LVs) have evolved as a safe and effective tool to deliver selective gene to halt PD progression..•This review will mainly focus on understanding the basic mechanism of action of LVs and its therapeutic aid in PD. Continual strategies to devise a complete therapeutic cure for neurodegenerative conditions has been a challenge, majorly due to the presence of blood brain barrier. Lack of targeted delivery in order to minimize loss of dopamine (DA) neurones has been a major challenge to overcome anomalies in Parkinson Disease (PD). PD is a neuromotor degenerative disorder deteriorating motor coordination in affected individuals. Recent research has highlighted the use of lentiviral vectors (LVs) for selective delivery of neuroprotective substance for complete halt of disease progression in PD. LVs have the ability to infect both dividing and non-dividing cells along with non-encoding capability of viral protein that might elicit an immune response. This review will mainly focus on understanding the basic mechanism of action of LVs and its therapeutic aid in PD.